Drug Approval | October 16, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Indoco is comprehensively working on the remedial action plan
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
WHO estimates suggest that 150 million people worldwide are affected by Trachoma
We now rank 3rd in pharmaceutical production by volume and 14th by value
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Subscribe To Our Newsletter & Stay Updated
